Autologous stem cell transplantation

Multiple Myeloma and Related Disorders

Volumn , Issue , 2004, Pages 250-259

  Harousseau, Jean Luc ^a   Attal, Michel ^b  

^a HÔTEL DIEU   (France)

^b CHU PURPAN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85057368808     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (53)

1. Bataille R, Harousseau JL. Multiple myeloma (review article). N Engl J Med 1997; 36:1657-64.
2. Harousseau JL, Attal M. The role of autologous hematopoietic stem cell transplantation in multiplemyeloma. Semin Hematol 1997; 34(Suppl 1):61-6.
3. Blade J, San Miguel JF, Montserrat F, Alcala A, Maldonado J, Garcia-Conde J, et al. Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/autotransplantation and who were conventionally treated. J Clin Oncol 1996; 14:2167-73.
4. Barlogie B, Jagannath S, Vesole D, Naucke S, Cheson B, Mattox S, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89:789-93.
5. Lenhoff S, Hjorth M, Holmberg E, Turesson I, Westin J, Nielsen JL, et al. Impact of survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma. Blood 2000; 95:7-11.
6. Palumbo A, Triolo S, Argentino C, Bringhen S, Dominietto A, Rus C, et al. Dose intensive melphalan with stem-cell support is superior to standard treatment in elderly myeloma patients. Blood 1999; 94:1248-53.
7. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335:91-7.
8. Fermand JP, Ravaud P, Katsahian S, Divine M, Leblond V, Belanger C, et al. High dose therapy and autologous blood stem cell transplantation versus conventional treatment in multiple myeloma: results of a randomized trial in 190 patients 55 to 65 years of age. Blood 1999; 94(Suppl 1):396a (abstract).
9. Blade J, Sureda A, Ribera JM, Diaz-Mediavilla J, Palomera L, Fernandez-Calvo J, et al. High-dose therapy autotransplantation/intensification vs. continued conventional chemotherapy in multiple myeloma in patients responding to initial treatment chemotherapy. Results of a prospective randomized trial from the Spanish Cooperative Group PETHEMA. Blood 2001; 98:815a (abstract).
10. 2) vs. oral melphalan/prednisone: an interim analysis. Blood 2001; 98:849a (abstract).
11. Child JA, Morgan GJ, Davies FC, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348:1875-83.
12. Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or resume treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998; 92:3131-6.
13. Barlogie B, Alexanian R, Dicke K, Zagars G, Spitzer G, Jagannath S, et al. High dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood 1987; 70:869-72.
14. Cunningham D, Paz-Ares L, Milan S, Powles R, Nicolson M, Hickish T, et al. High dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol 1994; 12:759-63.
15. 2 as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma. Final analysis of the IFM 95-02 randomized trial. Blood 2002; 99:731-5.
16. Goldschmidt H, Hegenbart U, Wallmeier M, Hohaus S, Engenhart R, Wannenmacher M, et al. High-dose therapy with peripheral blood progenitor cell transplantation in multiple myeloma. Ann Oncol 1997; 8:243-6.
17. Bjorkstrand B, Svensson H, Goldschmidt H, Ljungman PT, Apperley J, Remes K, Ljungman PT, Apperley J, Remes K, et al. 5489 autotransplants in multiple myeloma: a registry from the EBMT. Blood 1999; 94(Suppl 1):714a (abstract).
18. 2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma. Bone Marrow Transplant 1999; 23:1000-6.
19. Moreau P, Harousseau JL, Wijdenes J, Morineau N, Milpied N, Bataille R. A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose Melphalan induces high complete response rate in advanced multiple myeloma. Br J Haematol 2000; 109:661-4.
20. Lahuerta JJ, Grande C, Blade J, Martinez-Lopez J, Alegre A, Garcia-Conde J, et al. Myeloablative treatments for multiple myeloma: update of comparative study of different regimens used in patients from the Spanish Registry for Transplantation in Multiple Myeloma. Leuk Lymphoma 2002; 43:67-74.
21. Harousseau JL, Milpied N, Laporte JP, Collombat P, Facon T, Tigaud JD, et al. Double intensive therapy in high-risk multiple myeloma. Blood 1992; 79:2827-33.
22. Vesole D, Barlogie B, Jagannath S, Cheson B, Tricot G, Alexanian R, et al. High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants. Blood 1994; 84:950-6.
23. Weaver CH, Zhen B, Schwartzberg LS, Leff R, Magee M, Geier L, et al. Phase I-II evaluation of rapid sequence tandem highdose melphalan with peripheral blood stem cell support in patients with multiple myeloma. Bone Marrow Transplant 1998; 22:245-51.
24. Bjorkstrand B, Ljungman P, Bird JM, Samson D, Gahrton G. Double high-dose chemoradiotherapy with autologous stem cell transplantation can induce molecular remission in multiple myeloma. Bone Marrow Transplant 1995; 15:367-71.
25. Vesole D, Tricot G, Jagannath S, Desikan KR, Siegel D, Bracy D, et al. Autotransplant in multiple myeloma: what have we learned? Blood 1996; 88:838-47.
26. Desikan R, Barlogie B, Sawyer J, Ayers D, Tricot G, Badros A, et al. Results of high dose therapy for 1000 patients with multiple myeloma: durable complete remission and superior survival in the absence of chromosome 13 abnormalities. Blood 2000; 95:4008-10.
27. Attal M, Harousseau JL, Facon T, et al. for the IFM. Single versus double transplant in myeloma: a randomized trial of the IFM. Proceeding of the VIIIth International Myeloma Workshop 2001, S15 p 28 (abstract).
28. Sonneveld P, Van Der Holt P, Sergeren CM, et al. Intensive versus double intensive therapy in untreated multiple myeloma: updated results of the prospective Phase III study Hovon 24 MM. Proceedings of the IXth Myeloma Workshop. Hematol J 2003; 4(Suppl 1):S59.
29. Cavo M, Zamagni E, Cellini C, et al. Single versus tandem autologous transplants in Multiple Myeloma: Italian experience. Proceedings of the IXth Myeloma Workshop. Hematol J 2003; 4(Suppl 1):S60.
30. Fermand JP, Marolleau JP, Alberti C, Divine M, Leblond V, Macro M, et al. Single versus tandem high dose therapy supported with autologous stem cell transplantation using unselected or CD 34 enriched ABSC: preliminary results of a two by two designed randomized trial in 23 young patients with multiple myeloma. Blood 2001; 98:815a (abstract).
31. Schiller G, Vescio R, Freytes C, Spitzer G, Sahebi F, Lee M, et al. Transplantation of CD 34+ peripheral blood progenitor cell after high-dose chemotherapy for patients with advanced multiple myeloma. Blood 1995; 86:390-7.
32. Lemoli RM, Fortuna A, Motta MR, Rizzi S, Giudice V, Nannetti A, et al. Concomittant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: positive selection and transplantation of enriched CD 34+ cells to remove circulating tumor cells. Blood 1996; 87:1625-34.
33. Vescio RA, Schiller G, Stewart K, Ballester O, Noga S, Rugo H, et al. Multicenter Phase III trial to evaluate CD 34 selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma. Blood 1999; 93:1858-68.
34. Stewart AK, Vescio K, Schiller G, Ballester O, Noga S, Rugo H, et al. Purging of autologous peripheral blood stem cells using CD34 selection does not improve overall or progression free survival after high-dose therapy for multiple myelome: results of a multicenter randomized controlle trial. J Clin Oncol 2001; 198:3771-9.
35. Goldschmidt H, Bouko Y, Bourhis JH, Greinix H, Salles G, Derigs G, et al. CD 34+ selected PBPCT results in an increased infective risk without prolongation of event free survival in newly diagnosed myeloma: a randomised study from the EBMT. Blood 2000; 96:558a (abstract).
36. Gazitt Y, Reading CC, Hoffman R, Wickrema A, Vesole DH, Jagannath S, et al. Purified CD 34+ Lin-thy stem cells do not contain clonal myeloma cells. Blood 1995; 86:381-9.
37. Tricot G, Gazitt Y, Leemhuis S, Jagannath S, Desikan KR, Siegel D, et al. Collection, tumor contamination and engraftment kinetics of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma. Blood 1998; 91:4489-95.
38. Tricot G, Jagannath S, Vesole D, Nelson J, Trindle S, Miller L, et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85:588-96.
39. Harousseau JL. Optimizing peripheral blood progenitor cell autologous transplantation in multiple myeloma. Haematologica 1999; 84:548-53.
40. Facon T, Harousseau JL, Maloisel F, Attal M, Odriozola J, Alegre A, et al. Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma: a randomized, controlled trial. Blood 1999; 94:1218-25.
41. Bjorkstrand B, Svensson H, Goldschmidt H, Ljungman P, Apperley JF, Mandelli F, et al. Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the EBMT. Bone Marrow Transplant 2001; 27:511-15.
42. Cunningham D, Powles R, Malpas J, Raje N, Milan S, Viner C, et al. A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long term follow-up results. Br J Haematol 1998; 102:195-202.
43. Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93:66-75.
44. Facon T, Avet-Loiseau H, Guillerm G, Moreau P, Genevieve F, Zan M, et al. Chromosome 13 abnormalities identified by Fish analysis and serum 2 microglobulin produce powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001; 97:1566-71.
45. Lahuerta JJ, Martinez-Lopez J, de la Serna J, Blade J, Grande C, Alegre A, et al. Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. Br J Haematol 2000; 109:438-46.
46. Davies FE, Forsyth PD, Rawstron AC, Owen RG, Pratt G, Evans PA, et al. The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma. Br J Haematol 2001; 112:814-19.
47. Siegel DS, Desikan KR, Mehta J, Singhal S, Fassas A, Munshi N, et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 1999; 93:51-4.
48. Badros A, Barlogie B, Siegel E, Morris C, Desikan R, Zangari M, et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 2001; 114:600-7.
49. Badros A, Barlogie B, Siegel E, Roberts J, Langmaid C, Zangari M, et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001; 114:822-9.
50. Tricot G, Alberts DS, Johnson C, Roe DJ, Dorr RT, Bracy D, et al. Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. Clin Cancer Res 1996; 2:947-52.
51. Ballester B, Tummala R, Janssen WE, Fields KK, Hiemenz JW, Goldstein SC, et al. High dose therapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal failure. Bone Marrow Transplant 1997; 20:653-6.
52. Tosi P, Zamagni E, Ronconi S, Benni M, Motta MR, Rizzi S, et al. Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure. Leukemia 2000; 14:1310-13.
53. San Miguel J, Lahuerta JJ, Garcia-Sanz R, Alegre A, Blade J, Martinez R, et al. Are myeloma patients with renal failure candidate for autologous stem cell transplantation. Hematol J 2000; 1:28-36.